Context: Evidence supports a protective effect of menopausal hormone therapy (HT) on bone. However, whether genetic susceptibility modifies the association of HT and fracture risk is not sufficiently explored.
M enopausal hormone therapy (HT) prevents bone loss and reduces fracture risk in postmenopausal women. The Women's Health Initiative (WHI) clinical trials demonstrated that estrogen alone or estrogen plus progestin (E+P) therapy reduced the risk of hip fracture by 33% to 35% and total fracture by 24% to 29% (1, 2) .
Evidence indicates that contributors to fracture risk are multifactorial and include both genetic and environmental factors (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . The majority of previous gene-environment interaction studies published on bone-related phenotypes have relied on a candidate gene approach, which has seldom been replicated because of small effect size and small sample size. Previous studies have demonstrated that an aggregate genetic risk score (GRS) based on common genetic variants identified from genome-wide association studies (GWASs) can be a useful measure of genetic susceptibility to fracture (6, 7) . In a meta-GWAS including 17 studies, a GRS with 16 single nucleotide polymorphisms (SNPs) that were associated with both bone mineral density (BMD) and fracture was associated with any type of fracture (6) . Another study showed that the GRS with 16 SNPs and the GRS based on 63 BMD SNPs identified from the meta-GWAS were associated with any type of fracture and hip fractures risk (7) . In a recent study by Ho-Le et al. (13) , a BMD GRS showed an increased fracture risk independent of age, prior fracture, and falls.
Given the strength of the evidence supporting a protective effect of HT on fracture risk, the existing meta-GWAS, and availability of the HT clinical trial data, we performed a gene-environment interaction study to untangle the complex interplay of genetic susceptibility and HT on risk of fracture. We hypothesized that genetic susceptibility modifies the association of HT and fracture risk.
Materials and Methods

WHI HT clinical trials
Between 1993 and 1998, 27,347 women participated in one of two WHI HT trials (14) . If a participant had had a hysterectomy (n = 10,739), she was randomized into the estrogenalone study (conjugated equine estrogen 0.625 mg/day or matching placebo) (15), whereas if she had an intact uterus (n = 16,608), she was randomized to the E+P study (conjugated equine estrogen 0.625 mg plus medroxyprogesterone acetate 2.5 mg/day or matching placebo). Because of the increased risk of breast cancer and inconsistent risk-benefit profiles, the E+P trial was ended in 2002 (median follow-up, 5.6 years) (16, 17) . The estrogen-alone trial was also terminated in 2004 (median follow-up, 7.2 years) because of the increased stroke risk with no evidence of coronary heart disease or global benefit (17, 18) . However, the women were followed until the planned stop date (March 31, 2005 ).
Study participants
Among 22,030 self-identified European American (EA) HT trial participants, 10,634 women were genotyped as part of one of two substudies: the Genomics and Randomized Trials Network (GARNET; N = 4,894) and the WHI Memory Study+ (WHIMS+; N = 5740). WHI GARNET was designed to identify genetic factors that impact treatment response to HT using a nested case-control study design. The WHIMS+ substudy includes WHIMS EA participants who are not in GARNET, plus additionally selected HT trial participants who are not in WHIMS or GARNET (19) . We oversampled for women age .65 years because all WHIMS participants are aged 65 and older (20) . All participants provided informed consent and the study was approved by the University at Buffalo Health Sciences institutional review board.
Among the 10,634 genotyped individuals, 701 were excluded before imputation in GARNET if sample-chromosome combination with chromosomal abnormalities and/or missingness .5% or overall missingness .2%, and were excluded in WHIMS+ if missingness .3% or were one of a related pair, leaving 9933 and 9932 self-reported white individuals with complete imputed SNP data available for fracture-associated variant GRS (Fx-GRS) and BMD-GRS, respectively. Data from an additional 11 individuals were excluded because of a lack of follow-up data. The current study includes data from the remaining 9922 (9921 for BMD-GRS analyses) women (Supplemental Fig. 1 ).
HT intervention
To classify women according to HT use, we used the assignment of HT at randomization. We combined the two hormone arms (estrogen alone and E+P) and classified the participants into two groups (randomized to HT intervention or placebo) because the findings of the two WHI HT trials on fracture prevention were similar (1, 2).
Ascertainment of fracture
The primary outcome of interest is incident fracture of any type. Fracture incidence was initially self-reported via semiannual questionnaires and adjudicated in a blind manner using radiology reports (1, 2) . Total fracture was defined as adjudicated fractures excluding those of the ribs, sternum, skull or face, fingers, toes, and cervical vertebrae (1, 2, 21) . For exploratory fracture subtype analyses, we considered the following three types: central body (hip, spine, and pelvis), lower limb (ankle, patella, shaft of femur, tarsal/metatarsal, tibia/ fibula, and tibial plateau), and upper limb (carpal, elbow, metacarpal, radius/ulna, upper radius/ulna, lower humerus, humerus, and upper humerus) (22) .
SNP genotyping, quality control, and imputation Samples were genotyped using the Illumina HumanOmni1-Quad v1-0 B SNP array (GARNET) or the Illumina HumanOmniExpressExome-8v1_B array (WHIMS+). In GARNET, SNPs were removed if they failed the recommended quality control (QC) procedure; intensity only, technical failure by the genotyping center, 100% missing, minor allele frequency = 0 for unrelated study participants, call rate ,98%, .0 discordant calls in 35 duplicate pairs, Hardy-Weinberg equilibrium P value ,1.0 3 10
24
. The genetic QC for WHIMS+ data was conducted following the Gene, Environment Association Studies Consortium protocol (23, 24) ; missing call rate $2%, Hardy-Weinberg equilibrium P value ,1.0 3 10 24 , and minor allele frequency ,0.01. Genotype imputation was conducted with Beagle software (25) using the 1000 Genomes reference panel (20100804 sequence and alignment release) (GARNET) and Minimac using the 1000 Genomes reference panel v3.20101123 (WHIMS+). Detailed quality control is described elsewhere (26) . Allelic dosage was calculated for the imputed genotype, ranging from 0 to 2.
GRSs
We constructed two GRSs, one for Fx-GRS SNPs and one for BMD-GRS SNPs, in which each GRS was weighted by allele effect size using SNPs that were identified in the Genetic Factors for Osteoporosis (GEFOS) consortium meta-GWAS (6) . The WHI Genetic Components of the HIP Fracture Consortium GWAS sample was included in the GEFOS meta-GWAS as a replication sample. The Fx-GRS was based on SNPs associated with femoral neck (FN) or lumbar spine BMD that were also associated with any type of fracture at Bonferroni-corrected significance level (P , 5 3 10 24 ) (Supplemental Table 1 ). In the fracture GRS, four SNPs were genotyped and 11 were imputed for GARNET, whereas two SNPs were typed and 13 were imputed for WHIMS+. A typed proxy (r 2 = 1) for rs1373004 (one), rs7898709, was used because the former SNP was not available in GARNET (WHIMS+) data (http://analysistools.nci.nih.gov/ LDlink/) (27) . Weights were calculated as a log-transformation of the reported odds ratios for fracture divided by the mean of log-transformed odds ratios across all GRS SNPs.
We constructed the BMD-GRS using 50 SNPs from an established set of 63 BMD-associated SNPs from the GEFOS meta-GWAS (Supplemental Table 2 ). In the score, a total of 13 (11) SNPs were typed, 36 (38) were imputed, and 1 (1) was a typed proxy in GARNET (WHIMS+). The typed proxy rs7898709 was again used for rs1373004. Of 63 SNPs, 13 variants were excluded for following reasons: failed QC (rs12821008, rs1566045, rs17040773), secondary signals showed only after conditional analysis but were not themselves associated with BMD (rs10226308, rs13245690, rs1564981, rs17482952, rs4792909, rs736825, rs7521902, rs7751941), or did not show an association with FN-BMD among females (beta-coefficient for FN-BMD, 0) (rs1878526, rs7071206). Weights for BMD-GRS were based on the stage 1 + 2 meta-analysis female-only effects sizes (beta-coefficients) for FN-BMD, which were standardized by dividing each beta-coefficient by the mean of the effects.
Statistical analyses
We compared the baseline characteristics between randomization arms using x 2 tests for categorical variables and t test for continuous variables. We used Cox proportional hazards regression to test the association of GRS with fracture and the interactions between HT and GRS on the risk of fracture. The analyses were conducted with both continuous and categorical parameterization of GRS. For the categorical analyses, participants were categorized into three groups based on GRS quartiles: quartile 1 (Q1), quartile 2 to 3 (Q2-3), and quartile 4 (Q4). The time-to-event was the number of days since enrollment to the first fracture. The proportional hazards assumptions were evaluated by examining Schoenfeld residuals; no relevant deviations were found. The multivariable models were adjusted for age and WHI GWAS (WHIMS+ or GARNET).
The joint effects of both GRS and HT on fracture risk were tested on both additive and multiplicative scales. Multiplicative interactions were examined by testing the statistical significance of the regression coefficient of the cross-product term while including both main effects in the model. Further, we assessed multiplicative interaction by evaluating the GRS-HT association in logistic regression models using a case-only approach with 1608 total fracture cases. The case-only study design increases power to detect gene-environment interaction because the need to estimate the association between gene and environment in noncases is alleviated under the assumption of gene-environment independence in the source population (28) . The gene-environment independence assumption was tested in logistic regression models with 8314 noncases and was satisfied.
To assess GRS-HT additive interactions, we constructed a composite variable of the previously mentioned GRS categories and HT arm and estimated the relative excess risk due to interaction (RERI) using the suggested methods by Li and Chambless (29) . We calculated strata-specific hazard ratios (HRs) and 95% confidence intervals (CIs) using those in the lowest GRS quartile who were assigned to HT intervention as the reference group. Variances of the RERI were calculated using the Hosmer and Lemeshow delta method (30) .
We further evaluated the HRs for HT intervention within the strata of GRSs to examine the effect modification of genetic susceptibility on the association between HT and fracture risk. Heterogeneity of the HT effect was tested using Cochran's Q test for meta-analysis.
All statistical analyses were conducted using SAS, version 9.4 (SAS Institute, Cary, NC). All P values reported were two-sided, and statistical significance was defined as P , 0.05.
Results
The baseline characteristics according to HT arm are summarized in Table 1 . As expected because of randomization, the intervention and placebo arms did not differ according to previous personal HT use, previous fracture, or in terms of physical measurements. Participants had a mean age of 67 years [standard deviation (SD), 6.5]. Approximately 66% had never used HT and 9% were current smokers at randomization. The mean (SD) GRSs were 14.7 (2.5) and 50.6 (4.8) for Fx-GRS and BMD-GRS, respectively, for participants without any fracture, and 14.9 (2.5) and 51.3 (4.7) for those with fracture incidence.
Both the Fx-GRS and BMD-GRS were significantly associated with total fracture incidence, confirming genetic associations with the meta-GWAS hits. Each unit increment in Fx-GRS from 16 SNPs resulted in a 4% increase hazards for total fracture (multivariate adjusted HR, 1.04; 95% CI, 1.02 to 1.06). For BMD-GRS, the HR was 1.03 (95% CI, 1.02 to 1.04) (Supplemental Table 3 ). In the analysis of categorical GRS, the annualized incidence rate of total fracture was 1.96%, 2.31%, and 2.49% in Fx-GRS Q1, Q2-3, and Q4, respectively. Similar results were observed for BMD-GRS. The annualized incidence rate of total fracture was 1.85%, 2.33%, and 2.59% in Q1, Q2-3, and Q4, respectively. Similar to total fracture, higher GRSs were associated with increased risk of all fracture subgroups. We did not observe any interaction between GRSs and age on fracture risk (Supplemental Table 4 ). We examined previous fracture, number of falls and smoking variables in the regression models; however, no factors significantly changed the effect estimate of GRS.
During an average follow-up of 7.1 (62.3) years, 698 women assigned to HT intervention and 910 women assigned to placebo experienced a fracture. The incidence rate of any fracture was 19 per 1000 person-years in the HT intervention group and 26 per 1000 person-years in the placebo group. Figure 1(a) and 1(b) shows that women assigned to placebo experienced higher fracture incidence compared with women randomized to HT intervention. In women assigned to placebo, we observed significant linear trends of higher fracture risk as genetic susceptibility increased. For Fx-GRS, these higher fracture risks ranged from HR, 1.26 (95% CI, 1.02 to 1.55) for the lowest genetic susceptibility group to HR, 1.75 (95% CI, 1.44 to 2.14) for the most genetically susceptible (P for trend ,0.001). The pattern was similar for the BMD-GRS with P for trend ,0.0001.
We observed a substantial additive interaction between the GRSs and HT. The joint effect of randomization to placebo and high genetic susceptibility on total fracture risk was larger than expected from the sum of the individual effects. The multivariable-adjusted RERI values were 0.35 (95% CI, 0.01 to 0.69; P = 0.047) for Q4 of Fx-GRS and 0.38 (95% CI, 0.01 to 0.75; P = 0.046) for Q4 for the BMD-GRS, indicating that those who were assigned to placebo are at higher risk of fracture if their genetic predisposition is high.
We found no evidence for statistically significant multiplicative interaction for either GRS on total fracture. In Cox proportional hazard regression, the multivariable adjusted P value for multiplicative interaction was 0.49 for Fx-GRS and 0.63 for BMD-GRS. The results from case-only analyses similarly showed no multiplicative interaction between GRS and HT (Fx-GRS P for interaction = 0.53; BMD-GRS P for interaction = 0.84).
When we compared the effect of HT intervention within GRS strata, a somewhat greater fracture risk reduction was observed in women with high genetic Fig. 2(a) ]. However, the difference among GRS strata was not statistically significant (P for heterogeneity = 0.40). We observed similar risk reductions in BMD-GRS quartile strata (24%, 24%, and 35% for BMD-GRS Q1, Q2-3, and Q4, respectively); however, the heterogeneity was statistically insignificant (P = 0.40) [ Fig. 2(b) ]. Supplemental Fig. 2 shows the Kaplan-Meier plots for the fracture and BMD GRSs, respectively. These plots show the highest cumulative hazards for women who were randomized to placebo, where women with the highest genetic susceptibility are at highest fracture risk. In exploratory analyses using fracture subgroups, we found no evidence for statistically significant multiplicative interaction for either score or any of the fracture sites (P for interaction . 0.05) (Supplemental Fig. 3) . However, we again noted a substantial additive Figure 1 . Joint effects of hormone therapy and genetic risk score on total fracture risk. HRs are for total incident fracture over a mean follow-up of 7.1 years. Cox regression models were adjusted for age (years) and WHI GWAS (GARNET or WHIMS+). Case-only analysis models were adjusted for age (years) and WHI GWAS (GARNET or WHIMS+). interaction between GRS and HT on the risk of central body and upper limb fracture in the highest GRS quartile (Fx-GRS Q4 P for RERI = 0.04 for upper limb fracture; BMD-GRS Q4 P for RERI = 0.01 for central body fracture) (data not shown). Relative risk reduction with HT use was stronger in women with high genetic predisposition in central and upper limb fracture, but the heterogeneity was not statistically significant.
Supplemental Table 5 shows the evidence for interaction of HT with single SNPs that make up the GRS. Three SNPs were nominally relevant (rs7812088 in ABCF2, rs1346004 in GALNT3, rs3801387 in WNT16) but not after adjusting for multiple testing.
Discussion
We examined cumulative effects of previously reported 16 SNPs associated with both BMD and fracture and 50 BMD-associated SNPs on fracture risk. We observed that higher fracture and BMD GRS are significantly associated with increased fracture risk and that there is a substantial additive interaction for both GRSs and HT use on risk of total fracture. Although statistically insignificant, we observed a trend toward greater total fracture risk reduction with HT use among the most genetically susceptible women. In exploratory analyses, we also found evidence of additive interaction for central body and upper limb fractures.
Our study confirms previous findings of cumulative main effects of the GEFOS meta-GWAS variants with fracture in our cohort of 9922 EA women. Estrada et al. (6) showed that a GRS based on 16 SNPs associated with both BMD and fracture had a relevant association with any fracture among elderly women. Furthermore, Erikson et al. (7) demonstrated that a GRS based on 63 BMD SNPs was also associated with the incidence of any type of fracture and of hip fractures in older participants. In our analyses, we constructed the BMD-GRS with 50 QC-passed SNPs that showed an association with FN-BMD among females while excluding variants that showed secondary conditional signals. Although we constructed BMD-GRS with a subset of 63 SNPs, our reported findings are in agreement with the previous studies. The results provide solid impetus for our gene-HT interaction study because these variants are meta-GWAS significant and replicated in our sample.
Within the context of a randomized placebo controlled trial, we were able to examine and formally test for the presence of interaction of HT and GRS on fracture on both additive and multiplicative scales. Our results suggest that the interaction between HT and genetic susceptibility is additive rather than multiplicative. Additive interaction is of a greater public health and clinical importance because it allows us to identify groups that may get more benefit from intervention through risk stratification.
Herein we found that women assigned to placebo had a higher risk of fracture; these risks were even more elevated in the presence of high genetic susceptibility. Our results point to the potential future benefit of genetic risk assessment in clinical decision-making for a targeted intervention, should our results be replicated in other studies. If replicated, these study findings may increase our evidence for the utility of genetic information as an additional factor to consider in evaluating the benefit-risk profile of osteoporosis treatment, and further contribute to our knowledge of personalized recommendations for fracture prevention. Benefits associated with other therapies such as bisphosphonates for osteoporosis prevention and treatment may also be greater in these high-risk women. In an observational study of 1023 postmenopausal Korean women, Lee et al. (31) analyzed GRS based on SNPs from a GEFOS meta-analysis (GRS63) for their predictability of fracture among women taking HT or bisphosphonates. Among women who were not on either treatment, those in the highest tertile had almost a 4 times increased risk of any incidental fracture compared with those in the medium and lowest tertiles, whereas there was no statistically significant increase in fracture risk with increase in genetic risk among women taking HT or bisphosphonates. Although further evaluation in other race/ethnic groups is required, findings from the study suggest that bisphosphonates as well as HT reduce the risk of fracture among women with at high genetic risk.
Estrogen deficiency causes imbalances in bone homeostasis, favoring bone resorption over formation, which leads to bone loss and susceptibility to fractures. Estrogen exerts effects on bone cells and the immune system (32) (33) (34) (35) (36) . Although some of the genes in the GRSs in our analyses are clustered within several biological bone-related pathways (6), the roles of most of these genes on bone response to HT use are largely unknown. Future large-scale studies are needed elucidate the biologic mechanism of interactions of genes with HT on fracture risk.
We observed stronger relative risk reduction with HT intervention by increasing GRS quartile level in total, central, and upper limb fracture, whereas the opposite was noted in lower limb fracture. Although we do not know the exact reason for this inconsistency, findings from the multicenter Study of Osteoporotic Fractures suggest that ankle fractures were not associated with total hip, total spine, and FN-BMD (37). In our sample, ankle fracture constituted approximately 35% of lower limb fracture. Major risk factors for ankle fractures include body weight and falls. Because both GRSs are derived from SNPs identified in the GEFOS for BMD, it is possible that some variants that account for fracture risk other than BMD such as falls are unrepresented. Therefore, analyses of a GRS that includes variants identified from future GWASs for fracture risk are necessary to improve fracture risk stratification at each anatomic site.
Our study investigated the gene-HT interaction on fracture risk in EA women using multiple genetic variants from a meta-GWAS and a powerful randomized clinical trial design. The random assignment of HT ensures that both known and unknown characteristics that can affect the outcome are uniformly distributed across intervention arms, thereby minimizing biases and confounding. In addition, the well-defined cohort, comprehensive and uniform data collection on participants' characteristics, prospective follow-up, and adjudicated fracture outcomes are strengths of our study.
Our study also has several limitations. First, both Fx-GRS and BMD-GRS in our analyses were derived from common variants identified in a meta-GWAS, which account for only a small portion of genetic variance in BMD (6, 7) . In addition, GRSs in our analyses account for BMDdependent SNPs only. Although BMD is the strongest predictor of fracture, fracture risk is multifactorial, and it is possible that some genetic variants that account for fracture risk are unrepresented. Another limitation of our study is the inability to determine the influence of BMD on the association of GRS and fracture risk in our sample because not all participants had their BMD measured. A previous study reported that, although the associations between GRS and risk of total fracture remained statistically significant after adjusting for clinical risk factors, the associations were attenuated after being adjusted for FN-BMD (13) . However, because assessment of a fracture risk prediction model for its clinical utility was not the purpose of our study, the BMD variable is not relevant in the current analyses. Further, we had limited power to investigate interactions in the fracture subtype analyses because of sample size. Last, we examined EA postmenopausal women only who enrolled in WHI HT trials; therefore, our findings may not be generalizable to other races/ethnic groups. We observed that the additive interaction was largely driven by the WHIMS+ sample, which is slightly older than the GARNET sample. However, we have lower power to detect the interaction when our sample is stratified, so we are cautious about drawing strong conclusions in this case.
Our results support further consideration of GRS as another factor in determining potential risk and benefit ratio of osteoporosis prevention and treatment. Future randomized trials of new osteoporosis treatments can benefit from the GRS-treatment interaction analysis to determine whether the additive interactions between genetic susceptibility and antiosteoporotic therapy exist and to assess the benefits of targeted treatment to women at the genetically highest fracture risk.
